Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof

Abstract

Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.

Description

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 13 / 690,828, filed Nov. 30, 2012, which is a continuation-in-part of U.S. patent application Ser. No. 13 / 560,612, filed Jul. 27, 2012, now abandoned, which is a continuation of U.S. patent application Ser. No. 12 / 687,038, filed Jan. 13, 2010, now abandoned, which is a continuation of U.S. patent application Ser. No. 11 / 188,281, filed Jul. 25, 2005, now abandoned, which is a continuation of U.S. patent application Ser. No. 10 / 103,423, filed Mar. 20, 2002, now abandoned, which claims priority to U.S. Provisional Patent Application No. 60 / 277,238, filed Mar. 20, 2001, all of which are incorporated herein by reference in their entirety.1. INTRODUCTION[0002]This invention relates generally to new activating receptors of the Ig super-family expressed on human myeloid cells, called TREM (triggering receptor expressed on myeloid cells) which are involved in immune and in...

AI Technical Summary

Benefits of technology

The patent text describes a transmembrane glycoprotein called TREM-2 that is selectively expressed on mast cells and dendritic cells, but not on granulocytes or monocytes. When TREM-2 is stimulated, it leads to the maturation of dendritic cells, makes them resistant to apoptosis (cell death), and increases their ability to respond to chemotactic signals. The invention provides isolated polypeptides or proteins that contain the same amino acid sequence as TREM-2, which can be used to regulate immune response and dendritic cell function.

Problems solved by technology

However, excessive secretion of pro-inflammatory mediators, together with overexpression of their receptors, cause excessive autocrine / paracrine activation of neutrophils and monocytes, leading to tissue damage and septic shock (Bone, R. C, 1991, Ann. Intern. Med 115:457-69; Beutler, B., Milsark, I. W. & Cerami, A. C, 1985, Science 229:869-71; Morrison, D. C. & Ryan, J. L., \9S7, Annu. Rev. Med 38:417-32; Tracey, K. J. et al., 1986, Science 234:470-74; Glauser, M. P., Zanetti, G., Baumgarmer, J. D. & Cohen, J., 1991, Lancet 338:732-36).

Images